Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Oncotype DX Stories

2013-09-19 10:13:05

Narratives about treatment processes and experiences inform patients without persuading Individuals often turn to others for advice when making choices. Perhaps, it seems fitting then, that individuals would seek out others when they are faced with important health decisions. Yet, health communicators have debated whether stories should be included in patient decision-aids (which are informational materials designed to help patients make educated choices about their health) because they...

2013-09-13 08:16:31

Assay accurately distinguishes patients at continued risk after five years of estrogen-blocking therapy from those who need no additional treatment A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of...

2013-09-09 16:23:45

Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, Calif. and AMSTERDAM, Sept. 9, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced that multiple established international breast cancer treatment guidelines confirmed that Agendia's MammaPrint(®) tests, the leading product in Agendia's Symphony suite of breast cancer tests, significantly augment prognostic and predictive information in making key cancer...

2013-08-22 08:26:56

The 13th St. Gallen International Expert Consensus Panel Report Emphasizes Oncotype DX's Unsurpassed Clinical Validation Supporting Greater Use and Reimbursement of the Test Worldwide GENEVA and REDWOOD CITY, Calif., Aug. 22, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the 13(th) St. Gallen International Breast Cancer Conference Expert Panel, for the second time, recognized the Oncotype DX(®) breast cancer test for its ability to provide not only...

2013-08-07 16:28:28

REDWOOD CITY, Calif., Aug. 7, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the Canaccord Genuity 33(rd) Annual Growth Conference in Boston on Wednesday, August 14 at 2:00 p.m. Eastern Time (ET). (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at...

2013-07-31 16:28:04

Product Revenue Increased 11% Compared to Prior Year REDWOOD CITY, Calif., July 31, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Product revenue was $63.7 million in the second quarter of 2013, compared with $57.2 million for the second quarter of 2012, an increase of 11 percent. Total revenue for the second...

2013-07-24 08:30:11

REDWOOD CITY, Calif., July 24, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, July 31 at 4:30 p.m. Eastern Time to discuss its second quarter 2013 financial results. The call and webcast will follow the release of the second quarter financial results after market close. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Conference Call DetailsTo access the live...

2013-07-11 16:24:45

Patient, physician and patient advocate representatives discuss innovations in personalized medicine and its impact on the future of health care WASHINGTON, July 11, 2013 /PRNewswire-USNewswire/ -- Results for Life (RFL), the educational branch of the American Clinical Laboratory Association, today convened a briefing on Capitol Hill to highlight the value and innovations taking place in the field of genetic and genomic testing. These tests mark the advent of personalized medicine -...

2013-07-01 11:26:29

Elevated HOXB13/IL17BR ratio may indicate who should receive extended treatment with letrozole A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. In their report being published online in the Journal of the National Cancer Institute, Massachusetts General Hospital (MGH) Cancer Center...

2013-06-03 08:27:25

Previstage(TM )GCC colorectal cancer test featured at the 2013 ASCO Annual Meeting QUEBEC CITY, June 3, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) today reported that results of a new study were presented on Sunday, June 2, during the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois. The abstract of the presentation entitled "Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage...